ǰÑÔ
ʳ¹Ü°©(esophageal carcinoma)ÊÇÓÉʳ¹ÜÁÛ×´ÉÏÆ¤»òÏÙÉÏÆ¤µÄÒì³£ÔöÉúËùÐγɵĶñÐÔ²¡±ä£¬ÆäÉú³¤Ò»Ñùƽ³£¾ÓÉÉÏÆ¤²»µä·¶ÔöÉú¡¢Ôλ°©¡¢½þÈ󰩵Ƚ׶Ρ£Ê³¹ÜÁÛ×´ÉÏÆ¤²»µä·¶ÔöÉúÊÇʳ¹Ü°©µÄÖ÷Òª°©Ç°²¡±ä£¬Óɲ»µä·¶ÔöÉúµ½°©±äÒ»Ñùƽ³£ÐèÒª¼¸ÄêÉõÖÁÊ®¼¸Äê¡£ÕýÓÉÓÚÔÆÔÆ£¬Ò»Ð©Ê³¹Ü°©¿ÉÒÔÔçÆÚ·¢Ã÷²¢¿ÉÍêÈ«ÖÎÓú¡£¹ØÓÚÍÌÑʲ»³©»òÓÐÒìÎï¸ÐµÄ»¼ÕßÓ¦¾¡Ôç¾ÙÐÐθ¾µ¼ì²éÒԱ㷢Ã÷ÔçÆÚʳ¹Ü°©»ò°©Ç°²¡±ä¡£³£Óö¯ÎïÄ£×ÓΪÓÕ·¢ÐÔʳ¹Ü°©¶¯ÎïÄ£×Ó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÑÇÏõ°·ÔÚÌåÄÚ¾ÓÉ´úл£¬±¬·¢ÖØÌ¼ÉÕ£¬Ê¹ºËËá»òÆäËû·Ö×Ó±¬·¢ÉÕ»¯¶øÖ°©£¬²î³Ø³ÆÑÇÏõ°·¿Ú·þ»ò賦Íâ¸øÒ©£¬¾ùÄÜÓÕ·¢´óÊóʳ¹Ü°©£¬¿ÉÓÃÓÚʳ¹Ü°©µÄ×éÖ¯±¬·¢ÆøÖÆ¡¢¿¹Ê³¹Ü°©Ò©ÎïµÄɸѡºÍʳ¹Ü°©±¬·¢Àú³ÌÖлúÌå·´Ó¦ÐÔµÄÑо¿¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1. ¼×»ùÜлùÑÇÏõ°·(methyl-benzyl-nitrosamine,MBNA)ÓÕ·¢Ê³¹Ü°© È¡ÌåÖØ100g£¨Ô¼1ÔÂÁ䣩ÒÔÉÏWistar´óÊó£¬ÈÎÆäÒûÓú¬MBNAÒûË®£¬²¢½«1% MBNAÈÜÒº¼ÓÔÚÉÙÁ¿µÄ·Ûĩ״ËÇÁÏÖУ¬½Á°èÔȳƣ¬Óɶ¯Îï×ÔÓÉÉãʳ£¬¸øÒ©Á¿ÎªÌìÌì0.75~1.5mg/kg, 80~100Ìì¿ÉÓÕ·¢Ê³¹Ü°©¡£
2. ¶þÌþ»ÆÕÁËØ(dihydrosafrole)ÓÕ·¢´óÊóʳ¹Ü°©Ä£×Ó ÔÚ´óÊóËÇÁÏÖмÓÈë΢Á¿2500~10 000ppm(1/2500~1/10 000)»ÆÕÁËØÎ¹Ñø´óÊó£¬ÓÕ·¢ÂÊ´ï20%~70%¡£
3. ÓÃ0.2£¥»ò0.005%MBNAË®ÈÜÒº£¬¸ø¶¯Î﾿ڹà飬ÌìÌìÒ»´Î£¬´óÊó¹à×¢¼ÁÁ¿Îª1mg/kgÌåÖØ£¬ÖÁµÚ27Ìì·ºÆðʳ¹ÜÈéÍ·×´Áö£¬154d·ºÆðʳ¹Ü°©£¬11¸öÔºóʳ¹Ü°©µÄ±¬·¢ÂÊΪ53%¡£
¡¾Ä£×ÓÌØµã¡¿£º
MBNAÓÕ·¢80~100Ìì¿É¼ûʳ¹ÜÁÛ״ϸ°û°©µÄ×éÖ¯ÏñºÍÈËÀàµÄʳ¹ÜÁÛ°©ÏàËÆ£¬µ«ºÜÉÙ±¬·¢×ªÒÆ£¬¸øÒ©Ê±¼äÓú³¤£¬°©µÄ±¬·¢ÂÊÓú¸ß£¬Ò»Ñùƽ³£¿É´ï80%~100%£¬Í¬Ê±MBNAÖ°©ÐÔ½ÏÇ¿£¬´ó¼ÁÁ¿1´Î¸øÒ©£¬¼´¿ÉÖ°©¡£ÔÚÄ£×ÓÖÆ±¸Àú³ÌÖÐÒª×¢ÖØ»¯Ñ§ÓÕµ¼¼ÁµÄÖÖÀàºÍ¶¯ÎïÆ·ÏµÑ¡Ôñ£¬Ñо¿·¢Ã÷ÏÖÔÚÓ¦ÓÃ×î¶àµÄÊÇ´óÊ󣬯äÖÐÓÖÒÔF344ºÍSprague Dawley´óÊóΪÖ÷¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ÑÇÏõ°·À໯ºÏÎïÊÇÒ»Ààǿְ©ÎÄÜÒýÆð¶àÔàÆ÷µÄÖ×Áö£¬ÆäÖÐijЩÖÖÀàµÄÑÇÏõ°·ÔÚ¶¯ÎïÌØÊâÊÇ´óÊóÌåÄÚÊǽÏÇ¿µÄʳ¹Ü°©ÓÕµ¼¼Á£¬ÕâЩ»¯ºÏÎïÖжԴóÊóʳ¹Ü×îÇ¿µÄÖ°©ÎïMBNA¹éÌØÊâµÄʳ¹ÜÇ׺ÍÐÔ£¬ËüÓÕµ¼µÄ°©±ä½öÏÞÓÚʳ¹Ü¡£MBNAÓÕµ¼µÄʳ¹Ü°©Ä£×ÓÖ÷ÒªÓÃÓÚÑо¿×éÖ¯²¡ÀíÑ§ÌØÕ÷ÒÔ¼°¾ÙÐа©±ä»úÖÆ¼°»¯Ñ§Ô¤·À·½ÃæµÄÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.ÎâÁÖ£¬³ÂÁÖÐË£¬³ÂÉ÷ÈÊ£®Ê³¹Ü°©¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®¹ú¼ÊÄ¥Á·Ò½Ñ§ÔÓÖ¾£¬2007,28 (5):433-435
2.Maliakal PP, Covil.le PF, Wanwimolruk S. Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine induced tumours. Drug Metabol Drug Interact, 2002, 19 (1):13-27